Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.diabres.2011.05.034
DC FieldValue
dc.titleDiabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know
dc.contributor.authorChan, J.C.N.
dc.contributor.authorChan, S.P.
dc.contributor.authorDeerochanawong, C.
dc.contributor.authorGo, R.T.
dc.contributor.authorLee, K.-O.
dc.contributor.authorMa, R.C.W.
dc.contributor.authorPan, C.-Y.
dc.contributor.authorSheu, W.H.-H.
dc.contributor.authorBarter, P.
dc.date.accessioned2016-07-10T02:36:12Z
dc.date.available2016-07-10T02:36:12Z
dc.date.issued2011-10
dc.identifier.citationChan, J.C.N., Chan, S.P., Deerochanawong, C., Go, R.T., Lee, K.-O., Ma, R.C.W., Pan, C.-Y., Sheu, W.H.-H., Barter, P. (2011-10). Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know. Diabetes Research and Clinical Practice 94 (1) : 1-13. ScholarBank@NUS Repository. https://doi.org/10.1016/j.diabres.2011.05.034
dc.identifier.issn01688227
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/125846
dc.description.abstractApproximately 77 million persons with diabetes reside in the Western Pacific Region. This number is estimated to rise to 113 million in 2030 with increasing burden of cardio-renal disease, affecting an increasingly young population. Randomized clinical trials have confirmed the benefits of using statins to reduce low-density lipoprotein cholesterol in preventing cardiovascular disease (CVD) in Caucasians, although similar data are lacking in Asia. Experts from the Western Pacific Region met and reviewed evidence regarding risk association of diabetic dyslipidaemia with cardio-renal disease, effects of lipid lowering, recommended guidelines and clinical practices in Asian populations. There is strong evidence supporting the role of diabetic dyslipidaemia in cardio-renal disease and the benefits of lipid lowering in these populations. The high rate of diabetic kidney disease, its close links with CVD, and the benefits of lipid lowering on renal function are particularly relevant to this population. While most national guidelines use criteria similar to the West in management of diabetic dyslipidaemia, there are consistently low rates of use of lipid-lowering drugs and attaining treatment goals in the region. The group recommends conducting randomized studies, strengthening of the health care system to promote early detection, and intervention of diabetic dyslipidaemia to prevent end organ damage. © 2011 Elsevier Ireland Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.diabres.2011.05.034
dc.sourceScopus
dc.subjectAsia
dc.subjectCardiovascular disease
dc.subjectCholesterol
dc.subjectDiabetes
dc.subjectDyslipidaemia
dc.subjectNephropathy
dc.subjectStatins
dc.typeReview
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.diabres.2011.05.034
dc.description.sourcetitleDiabetes Research and Clinical Practice
dc.description.volume94
dc.description.issue1
dc.description.page1-13
dc.description.codenDRCPE
dc.identifier.isiut000296529100009
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

14
checked on Feb 18, 2020

WEB OF SCIENCETM
Citations

14
checked on Feb 18, 2020

Page view(s)

59
checked on Feb 21, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.